

Hyperprogressive Disease Is a New Pattern of Progression After Anti-PD-1/PD-L1

Clinical Cancer Research

23, 1920-1928

DOI: [10.1158/1078-0432.ccr-16-1741](https://doi.org/10.1158/1078-0432.ccr-16-1741)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches. <i>Lung Cancer</i> , 2017, 106, 70-75.	0.9	30
2	Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence. <i>Medical Oncology</i> , 2017, 34, 34.	1.2	25
3	Can an Immune Checkpoint Inhibitor (Sometimes) Make Things Worse?. <i>Clinical Cancer Research</i> , 2017, 23, 1879-1881.	3.2	18
4	Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, 1605-1611.	0.6	474
5	Optimizing drug development in oncology by clinical trial simulation: Why and how?. <i>Briefings in Bioinformatics</i> , 2018, 19, 1203-1217.	3.2	10
6	Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?. <i>BMC Medicine</i> , 2017, 15, 55.	2.3	65
7	CD8 T cell regulation by T regulatory cells and the programmed cell death protein 1 pathway. <i>Immunology</i> , 2017, 151, 146-153.	2.0	12
8	Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. <i>Clinical Cancer Research</i> , 2017, 23, 4242-4250.	3.2	704
9	Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 5074-5081.	3.2	120
10	Negative predictive biomarkers of checkpoint inhibitors in hyper-progressive tumors. <i>Biomarkers in Medicine</i> , 2017, 11, 819-821.	0.6	3
11	Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 5729-5736.	3.2	172
12	Nonconventional patterns of benefit of solid tumors treated with PD-(L)1 inhibitors: a systematic review. <i>Immunotherapy</i> , 2017, 9, 995-1004.	1.0	14
13	Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence. <i>Scientific Reports</i> , 2017, 7, 7952.	1.6	71
14	Genomics of Immunotherapy-Associated Hyperprogressors Letter. <i>Clinical Cancer Research</i> , 2017, 23, 6374-6375.	3.2	11
15	Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 13-21.	2.0	56
16	Tumor cell-associated immune checkpoint molecules – Drivers of malignancy and stemness. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 571-583.	3.3	54
17	Genomics of Immunotherapy-Associated Hyperprogressors Response. <i>Clinical Cancer Research</i> , 2017, 23, 6376-6376.	3.2	8
18	Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1477-1490.	0.9	24

#	ARTICLE	IF	CITATIONS
19	Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy. <i>Lung Cancer</i> , 2017, 113, 4-6.	0.9	46
20	Refining Immunotherapy Approvals. <i>Clinical Cancer Research</i> , 2017, 23, 4948-4949.	3.2	9
21	Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?. <i>Cancer Treatment Reviews</i> , 2017, 60, 60-68.	3.4	125
22	Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities. <i>Clinical Cancer Research</i> , 2017, 23, 4992-5002.	3.2	41
23	The Current Role of Whole Brain Radiation Therapy in Non-“Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1467-1477.	0.5	18
24	How to emerge from the conservatism in clinical research methodology?. <i>Current Opinion in Oncology</i> , 2017, 29, 400-404.	1.1	2
25	Immunotherapy. <i>Otolaryngologic Clinics of North America</i> , 2017, 50, 867-874.	0.5	4
26	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. <i>Current Oncology Reports</i> , 2017, 19, 64.	1.8	106
27	Network meta-analysis of second-line treatment in metastatic renal cell carcinoma: efficacy and safety. <i>Future Oncology</i> , 2017, 13, 2709-2717.	1.1	6
28	Precision Oncology: Between Vaguely Right and Precisely Wrong. <i>Cancer Research</i> , 2017, 77, 6473-6479.	0.4	56
29	De-novo and acquired resistance to immune checkpoint targeting. <i>Lancet Oncology</i> , The, 2017, 18, e731-e741.	5.1	568
30	Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives. <i>European Journal of Cancer</i> , 2017, 87, 101-112.	1.3	56
31	Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. <i>European Urology</i> , 2017, 72, 411-423.	0.9	89
32	Tumor Response Dynamics of Advanced Non-“small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. <i>Clinical Cancer Research</i> , 2017, 23, 5737-5744.	3.2	69
33	Traitement de premiÃre ligne et de maintenance dans les CBNPC avancÃs en lâ™absence dâ™addiction oncogÃnique. <i>Revue Des Maladies Respiratoires Actualites</i> , 2017, 9, 234-247.	0.0	0
34	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. , 2017, 5, 100.		114
36	Promising cancer drugs may speed tumours in some patients. <i>Nature</i> , 2017, 544, 13-14.	13.7	12
37	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. <i>Frontiers in Immunology</i> , 2017, 8, 1597.	2.2	225

#	ARTICLE	IF	CITATIONS
38	The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. International Journal of Molecular Sciences, 2017, 18, 1374.	1.8	47
39	Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Frontiers in Oncology, 2017, 7, 72.	1.3	122
41	PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. Journal of Hematology and Oncology, 2017, 10, 146.	6.9	77
42	Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. Translational Lung Cancer Research, 2017, 6, S8-S20.	1.3	97
43	Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. Oncotarget, 2017, 8, 110693-110707.	0.8	115
44	Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget, 2017, 8, 91779-91794.	0.8	298
45	Pembrolizumab in Small-Cell Lung Cancer: In Search of the Best Biomarker. Journal of Clinical Oncology, 2017, 35, 3794-3795.	0.8	1
46	Impact of Variability in Portal Venous Phase Acquisition Timing in Tumor Density Measurement and Treatment Response Assessment: Metastatic Colorectal Cancer as a Paradigm. JCO Clinical Cancer Informatics, 2017, 1, 1-8.	1.0	17
47	Bending the Curve of Advanced Urothelial Carcinoma. Journal of Oncology Practice, 2017, 13, 319-320.	2.5	0
48	A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC. Journal of Thoracic Disease, 2017, 9, E292-E294.	0.6	0
49	Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, 2579-2586.	0.6	51
50	Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC. Cancer Treatment Reviews, 2018, 65, 65-77.	3.4	33
51	Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer. Future Oncology, 2018, 14, 1547-1558.	1.1	4
52	Promises and challenges of immuno-oncology from a clinical perspective. Japanese Journal of Clinical Oncology, 2018, 48, 101-102.	0.6	1
53	Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. Oncologist, 2018, 23, 540-555.	1.9	57
54	Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. Journal of Cellular Physiology, 2018, 233, 6337-6343.	2.0	91
55	Pitfalls in the radiological response assessment of immunotherapy. Memo - Magazine of European Medical Oncology, 2018, 11, 138-143.	0.3	59
56	A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics. Clinical Cancer Research, 2018, 24, 3292-3298.	3.2	41

#	ARTICLE	IF	CITATIONS
57	Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876209.	1.4	102
58	Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours. European Journal of Cancer, 2018, 95, 68-74.	1.3	24
60	The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity. Journal of Neuro-Oncology, 2018, 138, 299-306.	1.4	37
61	Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions. Cancer Treatment Reviews, 2018, 64, 21-29.	3.4	37
62	Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma. European Journal of Cancer, 2018, 91, 136-144.	1.3	32
63	Epigenetic modifiers as new immunomodulatory therapies in solid tumours. Annals of Oncology, 2018, 29, 812-824.	0.6	73
64	Progress in the Management of Advanced Thoracic Malignancies in 2017. Journal of Thoracic Oncology, 2018, 13, 301-322.	0.5	43
65	Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy. Lung Cancer, 2018, 117, 64-69.	0.9	13
66	Pembrolizumab for the treatment of bladder cancer. Expert Review of Anticancer Therapy, 2018, 18, 107-114.	1.1	12
67	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. Oncologist, 2018, 23, 410-421.	1.9	23
68	Immune Therapies in Phase 1 Trials. , 2018, , 547-563.		0
69	Chemoimmunotherapy in Metastatic Urothelial Carcinoma. European Urology, 2018, 73, 760-762.	0.9	0
70	The current evidence for a biomarker-based approach in cancer of unknown primary. Cancer Treatment Reviews, 2018, 67, 21-28.	3.4	30
71	OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis. Oncoimmunology, 2018, 7, e1465164.	2.1	3
72	Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. European Journal of Cancer, 2018, 96, 91-104.	1.3	94
73	Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors. Molecular Cancer Therapeutics, 2018, 17, 1602-1612.	1.9	6
74	Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report. Drug Safety - Case Reports, 2018, 5, 12.	0.9	15
75	Pseudoprogression and hyperprogression after checkpoint blockade. International Immunopharmacology, 2018, 58, 125-135.	1.7	121

#	ARTICLE	IF	CITATIONS
76	Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. <i>World Journal of Urology</i> , 2018, 36, 1703-1709.	1.2	71
77	Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. <i>Cancer Treatment Reviews</i> , 2018, 65, 78-86.	3.4	32
78	Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. <i>European Journal of Cancer</i> , 2018, 94, 179-186.	1.3	82
79	Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer. <i>Journal of Geriatric Oncology</i> , 2018, 9, 494-500.	0.5	18
80	¹⁸ F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor. <i>Journal of Nuclear Medicine</i> , 2018, 59, 15-24.	2.8	102
81	Clinical decision-making for immunotherapy in metastatic renal cell carcinoma. <i>Current Opinion in Urology</i> , 2018, 28, 29-34.	0.9	11
82	PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD - 1 gene. <i>Gene</i> , 2018, 638, 20-25.	1.0	87
83	Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab. <i>Clinical Lung Cancer</i> , 2018, 19, e171-e176.	1.1	56
84	Emerging biomarkers for cancer immunotherapy in melanoma. <i>Seminars in Cancer Biology</i> , 2018, 52, 207-215.	4.3	42
85	Immune correlates of clinical outcome in melanoma. <i>Immunology</i> , 2018, 153, 415-422.	2.0	9
86	Nivolumab in recurrent/metastatic head and neck cancers. <i>Future Oncology</i> , 2018, 14, 603-609.	1.1	3
87	Blockade of Tumor-Expressed PD-1 promotes lung cancer growth. <i>Oncolimmunology</i> , 2018, 7, e1408747.	2.1	99
88	Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. <i>Nature Reviews Urology</i> , 2018, 15, 112-124.	1.9	73
89	Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2018, 24, 1785-1794.	3.2	42
90	Immunotherapeutic Biomarkers and Selection Strategies. <i>Current Cancer Research</i> , 2018, , 69-114.	0.2	0
91	Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials. <i>Oncolimmunology</i> , 2018, 7, e1396403.	2.1	60
92	Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials. <i>Current Cancer Research</i> , 2018, , 243-280.	0.2	0
93	Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers. <i>Laboratory Investigation</i> , 2018, 98, 41-50.	1.7	30

#	ARTICLE	IF	CITATIONS
94	Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting. Seminars in Cancer Biology, 2018, 52, 166-177.	4.3	11
95	PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood, 2018, 131, 68-83.	0.6	311
96	Cancer Care Treatment Outcome Ontology: A Novel Computable Ontology for Profiling Treatment Outcomes in Patients With Solid Tumors. JCO Clinical Cancer Informatics, 2018, 2, 1-14.	1.0	7
97	Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 1019-1029.	1.8	55
98	Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials. Journal of Clinical Oncology, 2018, 36, 1798-1804.	0.8	27
99	Analysis of <i>MDM2</i> Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. JCO Precision Oncology, 2018, 2018, 1-14.	1.5	39
100	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of Clinical Oncology, 2018, 36, 633-641.	0.8	1,109
101	Keeping Expectations in Check With Immune Checkpoint Inhibitors. Journal of Clinical Oncology, 2018, 36, 1654-1657.	0.8	38
102	Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). Journal of Clinical Oncology, 2018, 36, 1412-1418.	0.8	324
103	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. Journal of Clinical Oncology, 2018, 36, 850-858.	0.8	288
104	Patterns of Response and Progression to Immunotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 169-178.	1.8	196
105	Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy. Journal of Thoracic Disease, 2018, 10, 1124-1128.	0.6	50
106	Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. Translational Lung Cancer Research, 2018, 7, 691-702.	1.3	8
107	Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC). Oncotarget, 2018, 9, 17554-17563.	0.8	21
108	Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers. Journal of Gastrointestinal Oncology, 2018, 9, 225-230.	0.6	2
109	Approach and management of checkpoint inhibitor-related immune hepatitis. Journal of Gastrointestinal Oncology, 2018, 9, 220-224.	0.6	28
110	Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. Journal of Thoracic Disease, 2018, 10, S1516-S1533.	0.6	57
111	Do immune checkpoint inhibitors need new studies methodology?. Journal of Thoracic Disease, 2018, 10, S1564-S1580.	0.6	58

#	ARTICLE	IF	CITATIONS
112	Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?. <i>Translational Lung Cancer Research</i> , 2018, 7, 631-638.	1.3	68
116	Nivolumab therapy for lung cancer with tracheo-parenchymal fistula. <i>Medicine (United States)</i> , 2018, 97, e13739.	0.4	6
118	Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer. <i>IScience</i> , 2018, 9, 258-277.	1.9	83
119	Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8239-8250.	1.0	32
120	Lung cancer, elderly and immune checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2018, 10, S1474-S1481.	0.6	25
121	Cancer research in the era of immunogenomics. <i>ESMO Open</i> , 2018, 3, e000475.	2.0	14
122	The continuing role of chemotherapy in the management of advanced urothelial cancer. <i>Therapeutic Advances in Urology</i> , 2018, 10, 455-480.	0.9	16
123	Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study. <i>Targeted Oncology</i> , 2018, 13, 611-619.	1.7	3
124	Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2857-2873.	2.0	10
125	Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma. <i>Oncotarget</i> , 2018, 9, 33043-33049.	0.8	13
126	Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. <i>Cancer Treatment Reviews</i> , 2018, 71, 8-18.	3.4	58
127	Adverse effects and radiological manifestations of new immunotherapy agents. <i>British Journal of Radiology</i> , 2019, 92, 20180164.	1.0	14
128	Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. <i>Frontiers in Pharmacology</i> , 2018, 9, 1050.	1.6	48
129	Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine. <i>Journal of Thoracic Disease</i> , 2018, 10, 1294-1299.	0.6	4
130	Hyperprogressive disease: recognizing a novel pattern to improve patient management. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 748-762.	12.5	304
132	Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. <i>Oncotarget</i> , 2018, 9, 8706-8715.	0.8	75
133	Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series. <i>Thoracic Cancer</i> , 2018, 9, 1782-1787.	0.8	23
134	Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma. <i>Cancers</i> , 2018, 10, 326.	1.7	23

#	ARTICLE	IF	CITATIONS
135	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 1543.	3.4	567
136	Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma. <i>Drugs</i> , 2018, 78, 1443-1457.	4.9	70
137	Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology. <i>Integrative Cancer Therapies</i> , 2018, 17, 1012-1015.	0.8	4
138	Molecular Diagnostics in Clinical Oncology. <i>Frontiers in Molecular Biosciences</i> , 2018, 5, 76.	1.6	93
139	Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. <i>Annals of Oncology</i> , 2018, 29, 2175-2182.	0.6	20
140	Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis. <i>Internal Medicine</i> , 2018, 57, 2217-2221.	0.3	34
141	Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. <i>World Journal of Urology</i> , 2018, 36, 1727-1740.	1.2	75
142	Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 129, 27-39.	2.0	39
143	Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. <i>PLoS ONE</i> , 2018, 13, e0195945.	1.1	46
144	The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 1-12.	2.0	16
145	Advances in geriatric oncology: a multidisciplinary perspective. <i>Tumori</i> , 2018, 104, 252-257.	0.6	6
146	High-Throughput Screening of Combinatorial Immunotherapies with Patient-Specific <i>In Silico</i> Models of Metastatic Colorectal Cancer. <i>Cancer Research</i> , 2018, 78, 5155-5163.	0.4	35
147	Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1569-1576.	0.5	206
148	A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy. <i>BMC Cancer</i> , 2018, 18, 620.	1.1	8
149	Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy. <i>Advanced Functional Materials</i> , 2018, 28, 1802540.	7.8	92
150	Immuno-Oncology: Emerging Targets and Combination Therapies. <i>Frontiers in Oncology</i> , 2018, 8, 315.	1.3	244
151	Renal Cell Carcinoma Pseudoprogression with Clinical Deterioration: To Hospice and Back. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 485-488.	0.9	9
152	The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance. <i>Cancer Management and Research</i> , 2018, Volume 10, 105-113.	0.9	45

#	ARTICLE	IF	CITATIONS
153	Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors. <i>Frontiers in Immunology</i> , 2018, 9, 797.	2.2	33
154	The Confluence of Sex Hormones and Aging on Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 1269.	2.2	178
155	Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. <i>Future Oncology</i> , 2018, 14, 2415-2431.	1.1	24
156	Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 6115-6124.	3.2	14
157	Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. <i>Future Oncology</i> , 2018, 14, 41-60.	1.1	12
158	Hyperprogression as a distinct outcome after immunotherapy. <i>Cancer Treatment Reviews</i> , 2018, 70, 16-21.	3.4	89
159	Synchronous multiple non-small cell lung cancers in an allograft lung recipient. <i>Lung Cancer</i> , 2018, 124, 291-292.	0.9	3
160	Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report. <i>BMC Urology</i> , 2018, 18, 26.	0.6	15
161	Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the "panacea" for all patients?. <i>BMC Medicine</i> , 2018, 16, 24.	2.3	11
162	PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. <i>Journal of Hematology and Oncology</i> , 2018, 11, 16.	6.9	96
163	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. , 2018, 6, 8.		936
164	Distinct Changes of BTLA and HVEM Expressions in Circulating CD4 ⁺ and CD8 ⁺ T Cells in Hepatocellular Carcinoma Patients. <i>Journal of Immunology Research</i> , 2018, 2018, 1-8.	0.9	27
165	Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). <i>Annals of Translational Medicine</i> , 2018, 6, 144-144.	0.7	19
166	A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. <i>Lancet Oncology</i> , The, 2018, 19, 1180-1191.	5.1	811
167	Review of checkpoint immunotherapy for the management of non-small cell lung cancer. <i>ImmunoTargets and Therapy</i> , 2018, Volume 7, 63-75.	2.7	48
168	Blocking the FSTL1-DIP2A Axis Improves Anti-tumor Immunity. <i>Cell Reports</i> , 2018, 24, 1790-1801.	2.9	35
169	Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?. <i>Journal of Translational Medicine</i> , 2018, 16, 219.	1.8	96
170	Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. <i>Cancer Management and Research</i> , 2018, Volume 10, 2475-2488.	0.9	22

#	ARTICLE	IF	CITATIONS
171	Immunotherapy and next-generation sequencing guided therapy for precision oncology: what have we learnt and what does the future hold?. Expert Review of Precision Medicine and Drug Development, 2018, 3, 205-213.	0.4	7
172	Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab. Immunotherapy, 2018, 10, 681-694.	1.0	31
173	Immune checkpoints and cancer in the immunogenomics era. Briefings in Functional Genomics, 2019, 18, 133-139.	1.3	19
174	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. Radiology, 2019, 293, 15-29.	3.6	45
175	PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. , 2019, 7, 209.		73
176	Embryonic Stem Cells Modulate the Cancer-Permissive Microenvironment of Human Uveal Melanoma. Theranostics, 2019, 9, 4764-4778.	4.6	11
177	Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction. Cancer Medicine, 2019, 8, 5399-5413.	1.3	15
178	Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy. Future Oncology, 2019, 15, 2645-2656.	1.1	10
179	Hyperprogression after immunotherapy in patients with malignant tumors of digestive system. BMC Cancer, 2019, 19, 705.	1.1	27
180	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
181	Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. , 2019, 7, 189.		41
182	Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy. Internal Medicine, 2019, 58, 3295-3298.	0.3	12
183	Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986269.	1.4	75
184	Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer. JAMA Network Open, 2019, 2, e197621.	2.8	25
185	The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy. Genome Medicine, 2019, 11, 43.	3.6	16
186	Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer. European Urology, 2019, 76, 524-532.	0.9	38
187	Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer1. Bladder Cancer, 2019, 5, 131-145.	0.2	11
188	Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. Targeted Oncology, 2019, 14, 453-463.	1.7	53

#	ARTICLE	IF	CITATIONS
189	Tumor intrinsic immunity related proteins may be novel tumor suppressors in some types of cancer. <i>Scientific Reports</i> , 2019, 9, 10918.	1.6	27
190	Lymph node metastasis matters. <i>Journal of Thoracic Disease</i> , 2019, 11, S331-S333.	0.6	1
191	Determinants of immunological evasion and immuncheckpoint inhibition response in non-small cell lung cancer: the genetic front. <i>Oncogene</i> , 2019, 38, 5921-5932.	2.6	27
192	Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: An autopsy case study. <i>Respiratory Medicine Case Reports</i> , 2019, 28, 100885.	0.2	7
193	Next-generation sequencing and biomarkers for gastric cancer: what is the future?. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984818.	1.4	9
195	Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1608-1618.	0.5	78
196	The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987554.	1.4	21
197	Complete response in patients with locally advanced rectal cancer after neoadjuvant treatment with nivolumab. <i>OncImmunity</i> , 2019, 8, e1663108.	2.1	44
198	Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1699.	1.7	81
199	Immunotherapy for head and neck cancer: Recent advances and future directions. <i>Oral Oncology</i> , 2019, 99, 104460.	0.8	202
201	A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed. <i>Cancers</i> , 2019, 11, 1782.	1.7	53
202	Prevalence of HIV infection among Chinese voluntary blood donors during 2010-2017: an updated systematic review and meta-analysis. <i>Transfusion</i> , 2019, 59, 3431-3441.	0.8	1
203	Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence. <i>EJNMMI Research</i> , 2019, 9, 78.	1.1	21
204	The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4263.	1.8	17
205	Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. <i>European Journal of Cancer</i> , 2019, 120, 65-74.	1.3	33
206	Immunotherapy and urothelial carcinoma: An overview and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 46-55.	2.0	20
207	Paradox-driven adventures in the development of cancer immunology and immunotherapy. <i>Genes and Diseases</i> , 2019, 6, 224-231.	1.5	3
208	Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies. <i>Pharmacoeconomics</i> , 2019, 37, 1537-1551.	1.7	12

#	ARTICLE	IF	CITATIONS
209	Hyperprogressive disease with immunotherapy: new directions. <i>Journal of Thoracic Disease</i> , 2019, 11, S1877-S1880.	0.6	6
210	Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition. <i>Journal of Clinical Medicine</i> , 2019, 8, 1596.	1.0	15
211	Radiation Therapy and Immune Modulation. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 233-248.	0.9	6
212	Cognate Nonlytic Interactions between CD8+ T Cells and Breast Cancer Cells Induce Cancer Stem Cell-like Properties. <i>Cancer Research</i> , 2019, 79, 1507-1519.	0.4	31
213	Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 291-300.	2.0	14
214	Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report. <i>Lung Cancer</i> , 2019, 129, 75-79.	0.9	113
215	Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e454-e460.	0.9	14
216	Clonal Deletion of Tumor-Specific T Cells by Interferon- γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. <i>Immunity</i> , 2019, 50, 477-492.e8.	6.6	93
217	Novel patterns of response under immunotherapy. <i>Annals of Oncology</i> , 2019, 30, 385-396.	0.6	343
218	Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis. <i>BioMed Research International</i> , 2019, 1-13.	0.9	21
219	Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer. <i>Immunotherapy</i> , 2019, 11, 769-782.	1.0	9
220	Who will suffer from hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. <i>Journal of Thoracic Disease</i> , 2019, 11, S1289-S1291.	0.6	6
221	Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer. <i>ESMO Open</i> , 2019, 4, e000488.	2.0	39
222	Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1171-1178.	2.0	48
223	Hyperprogression during immunotherapy: do we really want to know?. <i>Annals of Oncology</i> , 2019, 30, 1028-1031.	0.6	17
224	Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date. <i>Cancer Management and Research</i> , 2019, Volume 11, 4893-4904.	0.9	10
225	Hyperprogression under Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2674.	1.8	96
226	Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	37

#	ARTICLE	IF	CITATIONS
227	Going to extremes: determinants of extraordinary response and survival in patients with cancer. <i>Nature Reviews Cancer</i> , 2019, 19, 339-348.	12.8	35
228	Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 517-529.	1.5	15
229	My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11579-11586.	3.3	15
230	Unique Case of Pseudoprogression Manifesting as Lung Cavitation After Pembrolizumab Treatment. <i>Journal of Thoracic Oncology</i> , 2019, 14, e108-e109.	0.5	17
231	Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy. <i>Cancers</i> , 2019, 11, 624.	1.7	32
232	Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. <i>BioMed Research International</i> , 2019, 2019, 1-15.	0.9	37
233	Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients. <i>Thoracic Cancer</i> , 2019, 10, 1303-1309.	0.8	12
234	The ABCs of preventing hyperprogressive disease after immunotherapy: awareness, biomarkers, and combination. <i>Journal of Thoracic Disease</i> , 2019, 11, S347-S351.	0.6	6
235	Hyperprogressive disease: a distinct effect of immunotherapy?. <i>Journal of Thoracic Disease</i> , 2019, 11, S262-S265.	0.6	17
236	PD1/PD-L1 inhibitor treatment for late stage non-small cell lung carcinoma, sometimes does more harm than good!. <i>Journal of Thoracic Disease</i> , 2019, 11, S396-S398.	0.6	2
237	<p>Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2505-2512.	1.0	17
238	PD-1⁺regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9999-10008.	3.3	655
239	Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. <i>Journal of Hematology and Oncology</i> , 2019, 12, 42.	6.9	58
240	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 63-144.	1.9	52
241	Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983992.	1.4	48
242	Emerging therapies for non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 45.	6.9	111
243	Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways. <i>Cell Death and Disease</i> , 2019, 10, 261.	2.7	52
244	Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1326.	1.8	43

#	ARTICLE	IF	CITATIONS
245	Hyperprogressionâ€”Immuno-therapy-Related Phenomenon vs Intrinsic Natural History of Cancer. <i>JAMA Oncology</i> , 2019, 5, 743.	3.4	7
246	Î±-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by Î±-TGFÎ² antibody to promote durable rejection and immunity in squamous cell carcinomas. , 2019, 7, 62.		121
247	Meeting the Challenge of Targeting Cancer Stem Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 16.	1.8	109
248	Immunotherapy of Melanoma: Facts and Hopes. <i>Clinical Cancer Research</i> , 2019, 25, 5191-5201.	3.2	181
249	Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2019, 26, 81-93.	0.9	38
250	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. <i>Immunotherapy</i> , 2019, 11, 515-529.	1.0	17
251	Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 65-71.	0.9	120
252	Dawn of precision medicine on gastric cancer. <i>International Journal of Clinical Oncology</i> , 2019, 24, 779-788.	1.0	15
253	A novel heterozygous large deletion of MSH6 gene in a Chinese family with Lynch syndrome. <i>Gene</i> , 2019, 704, 103-112.	1.0	7
254	Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 1104-1113.	0.6	205
255	Programmed cell death proteinâ€”1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1323-1333.	1.9	106
256	Are we ready to describe response or progression to immunotherapy in lung cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 112-119.	2.0	10
257	Hyperprogression after pembrolizumab treatment in two patients with metastatic urothelial carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 473-476.	0.6	8
258	Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. <i>Targeted Oncology</i> , 2019, 14, 205-221.	1.7	72
259	YWHAZ amplification/overexpression defines aggressive bladder cancer and contributes to chemo- and radio-resistance by suppressing caspase-mediated apoptosis. <i>Journal of Pathology</i> , 2019, 248, 476-487.	2.1	17
260	Hyperprogression in Pediatric Melanoma Metastatic to the Breast Treated with a Checkpoint Inhibitor. <i>Cureus</i> , 2019, 11, e3859.	0.2	7
261	Immune profiling reveals the diverse nature of the immune response in NSCLC and reveals signaling pathways that may influence the anti-tumor immune response. <i>Experimental and Molecular Pathology</i> , 2019, 109, 1-15.	0.9	4
262	Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 328-331.	0.5	31

#	ARTICLE	IF	CITATIONS
263	FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 292.	2.2	111
264	Nivolumab-refractory patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 130, 128-134.	0.9	16
265	Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer. <i>Immunity</i> , 2019, 50, 302-316.	6.6	455
266	Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients' treatment. <i>Journal of Thoracic Disease</i> , 2019, 11, 35-38.	0.6	28
267	The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018. <i>Acta Oncologica</i> , 2019, 58, 1-8.	0.8	14
268	Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1092-1098.	2.0	79
269	Hyperprogression with immunotherapy: Is it real?. <i>Cancer</i> , 2019, 125, 1218-1220.	2.0	17
270	Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , 2019, 125, 1341-1349.	2.0	115
271	Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 457-467.	1.4	7
272	Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis. <i>ERJ Open Research</i> , 2019, 5, 00179-2019.	1.1	20
273	Hyperprogression after immunotherapy. <i>South Asian Journal of Cancer</i> , 2019, 08, 244-246.	0.2	10
274	Unique behavior of brain metastases during the treatment of nivolumab for metastatic renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S267-S267.	0.7	1
275	How to recognize and manage hyper-progression and pseudo-progression during immune checkpoint blockade in non-small cell lung cancer. <i>Precision Cancer Medicine</i> , 2019, 2, 35-35.	1.8	3
276	Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy. <i>Medicina (Lithuania)</i> , 2019, 55, 743.	0.8	1
277	Durvalumab-Induced Hyperprogressive Disease in Nonmetastatic Lung Cancer. <i>Journal of Oncology Practice</i> , 2019, 15, 217-219.	2.5	3
278	Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response. <i>Radiology Imaging Cancer</i> , 2019, 1, e190031.	0.7	22
279	MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment. , 2019, 7, 327.		88
280	Heterogeneous response to target therapy in metastatic papillary renal cell carcinoma evaluated by morphologic and metabolic multimodality imaging. <i>Medicine (United States)</i> , 2019, 98, e18093.	0.4	3

#	ARTICLE	IF	CITATIONS
281	Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, 535-543.	0.7	48
282	Biomarker for personalized immunotherapy. <i>Translational Lung Cancer Research</i> , 2019, 8, S308-S317.	1.3	7
283	Editorial: Lymphocyte Functional Crosstalk and Regulation. <i>Frontiers in Immunology</i> , 2019, 10, 2916.	2.2	6
284	Isolation and Identification of Cancer Stem-Like Cells in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Pilot Study. <i>Frontiers in Oncology</i> , 2019, 9, 1394.	1.3	35
285	Personal response to immune checkpoint inhibitors of patients with advanced melanoma explained by a computational model of cellular immunity, tumor growth, and drug. <i>PLoS ONE</i> , 2019, 14, e0226869.	1.1	12
286	Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer. <i>Anti-Cancer Drugs</i> , 2019, 30, 1067-1070.	0.7	5
287	Treatment of inoperable elderly head and neck cancer patients. <i>Current Opinion in Oncology</i> , 2019, 31, 152-159.	1.1	11
288	Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma. <i>Medicine (United States)</i> , 2019, 98, e16417.	0.4	28
289	<p>Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8873-8877.	1.0	10
290	CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?. <i>Translational Lung Cancer Research</i> , 2019, 8, S464-S467.	1.3	2
291	Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018. <i>Translational Lung Cancer Research</i> , 2019, 8, 1091-1106.	1.3	27
292	Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder. <i>Clinical and Translational Oncology</i> , 2019, 21, 280-288.	1.2	6
293	Antibodyâ€“Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. <i>Clinical Cancer Research</i> , 2019, 25, 989-999.	3.2	315
294	Cancer Immunotherapy of TLR4 Agonistâ€“Antigen Constructs Enhanced with Pathogenâ€“Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PDâ€“L1. <i>Small</i> , 2019, 15, e1803993.	5.2	44
295	Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. <i>Gynecologic Oncology</i> , 2019, 152, 251-258.	0.6	33
296	Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. <i>Radiology</i> , 2019, 290, 9-22.	3.6	147
297	Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. <i>Clinical Cancer Research</i> , 2019, 25, 2166-2173.	3.2	67
298	Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. <i>Molecular Cancer</i> , 2019, 18, 10.	7.9	810

#	ARTICLE	IF	CITATIONS
299	Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 239-253.	5.1	342
300	Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma. <i>Journal of Medical Economics</i> , 2019, 22, 531-544.	1.0	15
301	Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series. <i>Immunotherapy</i> , 2019, 11, 167-175.	1.0	33
302	Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 793-802.	2.7	124
303	Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. <i>Clinical and Translational Oncology</i> , 2019, 21, 702-712.	1.2	38
304	Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 448-458.	1.9	63
305	FDG PET/CT for assessing tumour response to immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 238-250.	3.3	194
306	Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy. <i>Cell Death and Differentiation</i> , 2020, 27, 117-129.	5.0	31
307	Hyperprogression after nivolumab for melanoma: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 244-251.	0.5	12
308	Hyperprogression after one dose of nivolumab in sinonasal cancer: A case report. <i>Laryngoscope</i> , 2020, 130, 907-910.	1.1	10
309	Combining epigenetic drugs with other therapies for solid tumours – past lessons and future promise. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 91-107.	12.5	283
310	Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. <i>Neuro-Oncology</i> , 2020, 22, 17-30.	0.6	94
311	Automated Identification of Optimal Portal Venous Phase Timing with Convolutional Neural Networks. <i>Academic Radiology</i> , 2020, 27, e10-e18.	1.3	11
312	Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e122-e133.	0.9	32
313	Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review. <i>Lung Cancer</i> , 2020, 139, 18-21.	0.9	7
314	Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). <i>Cancer</i> , 2020, 126, 260-270.	2.0	202
316	Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models. <i>Clinical Cancer Research</i> , 2020, 26, 1787-1795.	3.2	51
317	iRECIST: how to do it. <i>Cancer Imaging</i> , 2020, 20, 2.	1.2	41

#	ARTICLE	IF	CITATIONS
318	Understanding genetic determinants of resistance to immune checkpoint blockers. <i>Seminars in Cancer Biology</i> , 2020, 65, 123-139.	4.3	9
319	Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma. <i>Oral Oncology</i> , 2020, 101, 104554.	0.8	18
320	Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study. <i>Anti-Cancer Drugs</i> , 2020, 31, 190-195.	0.7	22
321	18F-Fludeoxyglucose PET/Computed Tomography for Assessing Tumor Response to Immunotherapy and Detecting Immune-Related Side Effects. <i>PET Clinics</i> , 2020, 15, 1-10.	1.5	20
322	Current Evidence on PET Response Assessment to Immunotherapy in Lymphomas. <i>PET Clinics</i> , 2020, 15, 23-34.	1.5	11
323	PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. <i>Biomedicine and Pharmacotherapy</i> , 2020, 121, 109625.	2.5	92
324	Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: A step-by-step approach. <i>European Journal of Radiology</i> , 2020, 122, 108743.	1.2	8
325	Molecular imaging biomarkers for immune checkpoint inhibitor therapy. <i>Theranostics</i> , 2020, 10, 1708-1718.	4.6	68
326	Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Qijoteâ€¦CLICaP). <i>Thoracic Cancer</i> , 2020, 11, 353-361.	0.8	36
327	Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer. <i>Oral Oncology</i> , 2020, 100, 104477.	0.8	9
328	Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1168-1182.	3.3	115
329	Management and outcomes of non-small cell lung cancer patients with rapid progression under second-line immune checkpoint inhibitors: ERORECI study (GFPC 2016â€¦04). <i>Cancer Medicine</i> , 2020, 9, 432-439.	3.3	3
330	Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. <i>Clinical Cancer Research</i> , 2020, 26, 1846-1855.	3.2	70
331	Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2020, 61, 821-826.	2.8	73
332	Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation. <i>Clinical Cancer Research</i> , 2020, 26, 6464-6474.	3.2	16
333	VEGFR2 Promotes Metastasis and PD-L2 Expression of Human Osteosarcoma Cells by Activating the STAT3 and RhoA-ROCK-LIMK2 Pathways. <i>Frontiers in Oncology</i> , 2020, 10, 543562.	1.3	22
334	Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. <i>Auris Nasus Larynx</i> , 2020, 47, 676-686.	0.5	11
335	DUPLICATE: Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. <i>Auris Nasus Larynx</i> , 2020, , .	0.5	1

#	ARTICLE	IF	CITATIONS
336	Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade. , 2020, 8, e001343.		64
337	<p>Application and Prospects of Molecular Imaging in Immunotherapy</p>. Cancer Management and Research, 2020, Volume 12, 9389-9403.	0.9	8
338	Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 2020, 7, 567950.	1.6	13
339	Treatment after progression in the era of immunotherapy. Lancet Oncology, The, 2020, 21, e463-e476.	5.1	115
340	Is Weak Acid Beneficial for Addressing Checkpoint Inhibitorâ€Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?. Cancer Control, 2020, 27, 107327482094429.	0.7	2
341	Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in nonâ€small cell lung cancer. Thoracic Cancer, 2020, 11, 3337-3345.	0.8	12
342	Immunotherapy in older patients with cancer. Biomedical Journal, 2021, 44, 260-271.	1.4	19
343	Immunotherapy for advanced hepatocellular carcinoma, where are we?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188441.	3.3	52
344	Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18â€12. Journal of Cancer Research and Clinical Oncology, 2020, 146, 3359-3369.	1.2	12
345	BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Gastroenterology Report, 2020, 8, 192-205.	0.6	59
346	Molecular gene mutation profiles, TMB and the impact of prognosis in Caucasians and east Asian patients with lung adenocarcinoma. Translational Lung Cancer Research, 2020, 9, 629-638.	1.3	10
347	Development of a fluorescent probe for the detection of hPD-L1. Journal of Bioscience and Bioengineering, 2020, 130, 431-436.	1.1	6
348	Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings. European Journal of Cancer, 2020, 136, 159-168.	1.3	13
349	Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer. Frontiers in Oncology, 2020, 10, 568279.	1.3	11
350	Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma. Cancer Biology and Therapy, 2020, 21, 1097-1104.	1.5	7
351	Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. Frontiers in Oncology, 2020, 10, 590058.	1.3	5
352	Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11. Medicine (United States), 2020, 99, e22323.	0.4	12
353	Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (donâ€™t) know. Journal of Experimental and Clinical Cancer Research, 2020, 39, 236.	3.5	44

#	ARTICLE	IF	CITATIONS
354	Iodine-125 radioactive particles antagonize hyperprogressive disease following immunotherapy. <i>Medicine (United States)</i> , 2020, 99, e22933.	0.4	3
355	Immune Checkpoint Inhibitor-Related Pneumonitis. <i>Respiration</i> , 2020, 99, 932-942.	1.2	30
356	Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency. <i>Frontiers in Immunology</i> , 2020, 11, 563622.	2.2	4
357	Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma. <i>Journal of Immunology Research</i> , 2020, 2020, 1-18.	0.9	12
358	CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095299.	1.4	23
359	Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade. , 2020, 8, e000763.		31
360	Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. <i>Radiology</i> , 2020, 297, 87-96.	3.6	70
361	Atezolizumab in a Cohort of pretreated, advanced, non-small cell lung cancer patients with rare Histological Subtypes (CHANCE trial). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091598.	1.4	5
362	Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2020, 20, 707.	1.1	23
363	Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas. <i>Journal of Clinical Oncology</i> , 2020, 38, 3051-3061.	0.8	106
364	Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy. <i>Tumori</i> , 2020, 107, 030089162094038.	0.6	8
365	Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer. <i>Clinical and Experimental Immunology</i> , 2020, 202, 353-362.	1.1	28
366	Is there a link between very early changes of primary and secondary lymphoid organs in ¹⁸ F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?. , 2020, 8, e000656.		21
367	Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience. <i>Journal of Computer Assisted Tomography</i> , 2020, 44, 619-626.	0.5	4
368	Atypical patterns of response and progression in the era of immunotherapy combinations. <i>Future Oncology</i> , 2020, 16, 1707-1713.	1.1	11
369	Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Thoracic Cancer</i> , 2020, 11, 2793-2803.	0.8	18
370	Mechanisms of Cancer Resistance to Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 1290.	1.3	159
371	Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. <i>European Urology</i> , 2020, 78, 822-830.	0.9	99

#	ARTICLE	IF	CITATIONS
372	Atypical response patterns in metastatic melanoma and renal cell carcinoma patients treated with nivolumab: A single center experience. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 107815522094964.	0.5	5
373	Immune Oncology Biomarkers in Lung Cancer: an Overview. <i>Current Oncology Reports</i> , 2020, 22, 107.	1.8	8
374	Hyperprogressive disease in advanced cancer patients with liver metastasis treated with PD-1 inhibitors: two case reports. <i>Annals of Translational Medicine</i> , 2020, 8, 1100-1100.	0.7	4
375	Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 556275.	1.3	6
376	Comparison of radiological criteria for hyperprogressive disease in response to immunotherapy. <i>Cancer Treatment Reviews</i> , 2020, 91, 102116.	3.4	12
377	Chemokine biology on immune checkpoint-targeted therapies. <i>European Journal of Cancer</i> , 2020, 137, 260-271.	1.3	13
378	The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 565086.	1.3	20
379	Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy. <i>Respiratory Medicine and Research</i> , 2020, 78, 100788.	0.4	2
380	Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6176.	1.8	19
381	Exceptional response to nivolumab of a heavily pre-treated patient with metastatic renal-cell cancer: from a case report to molecular investigation and future perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094615.	1.4	0
382	Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer. <i>JAMA Network Open</i> , 2020, 3, e2011818.	2.8	26
383	Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma. , 2020, 8, e000627.		13
384	Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy. <i>Current Oncology Reports</i> , 2020, 22, 116.	1.8	9
385	Pseudoprogession and hyperprogression in lung cancer: a comprehensive review of literature. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3269-3279.	1.2	30
386	FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab. <i>Clinical Nuclear Medicine</i> , 2020, 45, 267-275.	0.7	12
388	Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer. <i>In Vivo</i> , 2020, 34, 2997-3003.	0.6	11
389	<p>A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies<p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6493-6509.	0.9	19
391	Understanding genomics and the immune environment of penile cancer to improve therapy. <i>Nature Reviews Urology</i> , 2020, 17, 555-570.	1.9	36

#	ARTICLE	IF	CITATIONS
392	An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy. , 2020, 8, e000661.		23
393	Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature. <i>Journal of Personalized Medicine</i> , 2020, 10, 88.	1.1	49
394	A rare case of hyperprogression of nonsmall cell lung cancer in a patient on atezolizumab therapy. <i>South Asian Journal of Cancer</i> , 2020, 09, 22-29.	0.2	1
395	PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma. <i>OncImmunity</i> , 2020, 9, 1844403.	2.1	18
396	The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 568931.	2.2	100
397	The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy. <i>Molecular Cancer</i> , 2020, 19, 81.	7.9	82
398	Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy. <i>Supportive Care in Cancer</i> , 2020, 28, 5569-5579.	1.0	15
399	A guide to cancer immunotherapy: from T cell basic science to clinical practice. <i>Nature Reviews Immunology</i> , 2020, 20, 651-668.	10.6	2,160
400	Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2020, 123, 81-91.	2.9	35
401	Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC. <i>Biomedicine and Pharmacotherapy</i> , 2020, 127, 109996.	2.5	35
402	Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1736-1752.	1.1	10
403	Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy. <i>BioDrugs</i> , 2020, 34, 463-476.	2.2	49
404	CD47: the next checkpoint target for cancer immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 103014.	2.0	52
405	Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses. <i>Frontiers in Oncology</i> , 2020, 10, 515.	1.3	20
406	Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. , 2020, 8, e000404.		29
407	Identification of a Gene-Related Risk Signature in Melanoma Patients Using Bioinformatic Profiling. <i>Journal of Oncology</i> , 2020, 2020, 1-13.	0.6	8
408	Therapeutically-induced stable disease in oncology early clinical trials. <i>PLoS ONE</i> , 2020, 15, e0233882.	1.1	1
409	Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093033.	1.4	25

#	ARTICLE	IF	CITATIONS
410	The Importance of Imaging Studies in the Assessment of Response to Immunotherapy in Lung Cancer. <i>Archivos De Bronconeumologia</i> , 2020, 56, 380-389.	0.4	1
411	Finding the hot spot: identifying immune sensitive gastrointestinal tumors. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 48-48.	1.5	6
412	Upcoming first-line chemotherapy for HER2-negative gastric cancer in Japan: which patients benefit from immunotherapy?. <i>Future Oncology</i> , 2020, 16, 1797-1799.	1.1	3
413	<p>Anti-PD-1 Therapy Achieved Disease Control After Multiline Chemotherapy in Unresectable KRAS-Positive Hepatoid Lung Adenocarcinoma: A Case Report and Literature Review</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4359-4364.	1.0	19
414	Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1039.	3.4	70
415	Effects of adaptive immune cell therapy on the immune cell profile in patients with advanced gastric cancer. <i>Cancer Medicine</i> , 2020, 9, 4907-4917.	1.3	2
416	Just eat it: A review of CD47 and SIRP-± antagonism. <i>Seminars in Oncology</i> , 2020, 47, 117-124.	0.8	50
417	Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia. <i>New England Journal of Medicine</i> , 2020, 382, 1150-1159.	13.9	7
418	Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6640-6650.	3.3	141
419	Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor. <i>Medicine (United States)</i> , 2020, 99, e19440.	0.4	3
420	Factors related to rapid progression of non-“small cell lung cancer in Chinese patients treated using single-“agent immune checkpoint inhibitor treatment. <i>Thoracic Cancer</i> , 2020, 11, 1170-1179.	0.8	16
421	How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?. <i>Frontiers in Immunology</i> , 2020, 11, 492.	2.2	40
422	Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 895-904.	5.2	111
423	TGF-beta: a master immune regulator. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 427-438.	1.5	101
424	Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors. <i>BMC Cancer</i> , 2020, 20, 207.	1.1	26
425	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 914-947.	0.5	119
426	Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 159.	2.2	73
427	MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma. <i>Cancers</i> , 2020, 12, 540.	1.7	55

#	ARTICLE	IF	CITATIONS
428	Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer. British Journal of Cancer, 2020, 123, 965-972.	2.9	53
429	<p>Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China</p>. OncoTargets and Therapy, 2020, Volume 13, 5191-5198.	1.0	3
430	Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication. , 2020, 8, e000793.		12
431	Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease. Journal of Cancer Research and Clinical Oncology, 2020, 146, 3025-3036.	1.2	14
432	Hyperprogressive disease in patients with advanced renal cell carcinoma: a new pattern of post-treatment cancer behavior. Immunologic Research, 2020, 68, 204-212.	1.3	5
433	Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors. JTO Clinical and Research Reports, 2020, 1, 100017.	0.6	0
434	Potential insights from population kinetic assessment of progression-free survival curves. Critical Reviews in Oncology/Hematology, 2020, 153, 103039.	2.0	3
435	Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, , .	0.8	3
436	Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. Cancers, 2020, 12, 344.	1.7	60
437	Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature. Oncologist, 2020, 25, 369-374.	1.9	13
438	Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. Cancer Medicine, 2020, 9, 2643-2652.	1.3	21
439	Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics. Scientific Reports, 2020, 10, 3565.	1.6	29
440	Assessing Treatment Benefit in Immuno-oncology. Statistics in Biosciences, 2020, 12, 83-103.	0.6	10
441	Predictive value of positron emission tomography for the prognosis of immune checkpoint inhibitors (ICIs) in malignant tumors. Cancer Immunology, Immunotherapy, 2020, 69, 927-936.	2.0	4
442	Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using 18F-FDG PET/CT. Journal of Nuclear Medicine, 2020, 61, 1404-1405.	2.8	9
443	Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?. Oncologist, 2020, 25, 94-98.	1.9	58
444	Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer. Clinical Colorectal Cancer, 2020, 19, 73-81.	1.0	36
445	Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review. Cancers, 2020, 12, 192.	1.7	30

#	ARTICLE	IF	CITATIONS
446	Nano-puerarin regulates tumor microenvironment and facilitates chemo- and immunotherapy in murine triple negative breast cancer model. <i>Biomaterials</i> , 2020, 235, 119769.	5.7	93
447	Competitive glucose metabolism as a target to boost bladder cancer immunotherapy. <i>Nature Reviews Urology</i> , 2020, 17, 77-106.	1.9	91
448	Radiological Monitoring of Modern Immunotherapy: A Novel Challenge for Interdisciplinary Patient Care. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2020, 192, 235-245.	0.7	7
449	Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. <i>Journal of Clinical Medicine</i> , 2020, 9, 286.	1.0	50
450	Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?. <i>Trends in Cancer</i> , 2020, 6, 181-191.	3.8	82
451	Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. <i>European Journal of Cancer</i> , 2020, 131, 40-50.	1.3	143
452	Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2 ⁺ negative endocrine-refractory metastatic breast cancer. , 2020, 8, e000173.		62
453	Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2856.	1.8	31
454	Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2623.	1.8	28
455	Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?. <i>Frontiers in Pharmacology</i> , 2020, 11, 441.	1.6	48
456	MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis. <i>ESMO Open</i> , 2020, 5, e000614.	2.0	24
457	Hyperprogressive disease observed in a subset of patients treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1599-1600.	2.0	0
458	Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2020, 22, 41.	1.8	20
459	Two-part joint model for a longitudinal semicontinuous marker and a terminal event with application to metastatic colorectal cancer data. <i>Biostatistics</i> , 2022, 23, 50-68.	0.9	7
460	Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial. <i>Trials</i> , 2020, 21, 352.	0.7	7
461	Hyperprogression Under Immune Checkpoint-Based Immunotherapy – Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model. <i>Cancers</i> , 2020, 12, 804.	1.7	19
462	Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2411.	1.8	28
463	Therapeutic Landscape of Metastatic Non-Small-Cell Lung Cancer in Canada in 2020. <i>Current Oncology</i> , 2020, 27, 52-60.	0.9	13

#	ARTICLE	IF	CITATIONS
464	Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?. <i>Clinical and Translational Oncology</i> , 2021, 23, 82-91.	1.2	3
465	A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment. <i>Clinical and Translational Oncology</i> , 2021, 23, 434-449.	1.2	6
466	Downregulation of Interferon- γ Receptor Expression Endows Resistance to Anti-Programmed Death Protein 1 Therapy in Colorectal Cancer. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 376, 21-28.	1.3	5
467	Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 74, 350-359.	1.8	122
468	Artificial Intelligence in Lung Cancer: Bridging the Gap Between Computational Power and Clinical Decision-Making. <i>Canadian Association of Radiologists Journal</i> , 2021, 72, 86-97.	1.1	24
469	Patterns of progression in patients treated for immuno-oncology antibodies combination. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 221-232.	2.0	12
470	From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer. <i>Immunotherapy</i> , 2021, 13, 67-77.	1.0	2
471	Re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. <i>Eur Urol</i> 2020;77:269-76. <i>European Urology</i> , 2021, 79, e17-e19.	0.9	1
472	Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103172.	2.0	8
473	Synergism between anti-angiogenic and immune checkpoint inhibitor drugs: A hypothesis. <i>Medical Hypotheses</i> , 2021, 146, 110399.	0.8	5
474	Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism. <i>Radiographics</i> , 2021, 41, 120-143.	1.4	27
475	The cutting-edge progress of immune-checkpoint blockade in lung cancer. <i>Cellular and Molecular Immunology</i> , 2021, 18, 279-293.	4.8	102
476	Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: An overview. <i>Pharmacological Research</i> , 2021, 164, 105309.	3.1	12
477	Clarification of Definitions of Hyperprogressive Disease During Immunotherapy. <i>JAMA Oncology</i> , 2021, 7, 136.	3.4	5
478	Hyperprogressive disease in patients receiving immune checkpoint inhibitors. <i>Current Problems in Cancer</i> , 2021, 45, 100688.	1.0	5
479	Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors. <i>International Journal of Cancer</i> , 2021, 149, 277-286.	2.3	7
480	Current status of immunotherapy for advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 20-27.	0.6	43
481	The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. <i>Cancer Cell</i> , 2021, 39, 154-173.	7.7	491

#	ARTICLE	IF	CITATIONS
482	Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft. <i>Molecular Cancer Research</i> , 2021, 19, 346-357.	1.5	6
483	The tumor-promoting effects of the adaptive immune system: a cause of hyperprogressive disease in cancer?. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 853-865.	2.4	8
484	Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 492-503.	3.2	76
485	Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1491-1496.	2.0	15
486	Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-d-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy. <i>Molecular Imaging and Biology</i> , 2021, 23, 139-147.	1.3	12
487	Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer. <i>In Vivo</i> , 2021, 35, 1865-1875.	0.6	4
488	Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy. <i>Investigational New Drugs</i> , 2021, 39, 1150-1158.	1.2	14
489	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th,) <i>TJ</i> 11, 0784314	1.8	3
490	Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy. <i>EClinicalMedicine</i> , 2021, 31, 100673.	3.2	23
491	IFN- γ and CD38 in Hyperprogressive Cancer Development. <i>Cancers</i> , 2021, 13, 309.	1.7	17
492	Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 203-215.	0.7	3
493	Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098406.	1.4	8
494	The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy. <i>BMC Cancer</i> , 2021, 21, 19.	1.1	24
495	Pulmonary complications of tyrosine kinase inhibitors and immune checkpoint inhibitors in patients with non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100439.	0.7	1
496	MDM2 inhibitors: Targeting p53-MDM2 interaction to anti-cancer. <i>E3S Web of Conferences</i> , 2021, 308, 02015.	0.2	0
497	Treatment evaluation and prognosis prediction using radiomics in clinical practice. , 2021, , 175-264.		0
498	MLH1 Exon 12 Gene Deletion Leading to Lynch Syndrome: A Case Report. <i>Oncology Research and Treatment</i> , 2021, 44, 414-421.	0.8	2
499	Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 621329.	1.3	11

#	ARTICLE	IF	CITATIONS
500	A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation. <i>Respiratory Medicine Case Reports</i> , 2021, 33, 101405.	0.2	6
501	Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings. , 2021, , 83-99.		0
502	Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Cancers</i> , 2021, 13, 286.	1.7	22
503	Are radiologists ready to evaluate true response to immunotherapy?. <i>Insights Into Imaging</i> , 2021, 12, 29.	1.6	5
504	Immunotherapy in non-small cell lung cancer: advancements and challenges. <i>Chinese Medical Journal</i> , 2021, 134, 1135-1137.	0.9	4
505	Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapy. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 230-240.	1.3	3
507	Nivolumab-caused hyperprogression of diffuse large B-cell lymphoma of the testis and spontaneous remission of type 2 diabetes mellitus in an elderly patient: a case report. <i>Anti-Cancer Drugs</i> , 2021, 32, 575-579.	0.7	1
508	Hyperprogressive Disease After Pembrolizumab Treatment in Advanced Epstein-Barr Virus-Associated Gastric Adenocarcinoma With ERBB2 Amplification. <i>JCO Precision Oncology</i> , 2021, 5, 370-377.	1.5	2
509	Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. <i>Lung Cancer</i> , 2021, 152, 109-118.	0.9	14
510	Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. , 2021, 9, e002092.		7
511	Dissociated response and clinical benefit in patients treated with nivolumab monotherapy. <i>Investigational New Drugs</i> , 2021, 39, 1170-1178.	1.2	11
512	Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 561083.	2.2	12
513	Identification and Validation of Efficacy of Immunological Therapy for Lung Cancer From Histopathological Images Based on Deep Learning. <i>Frontiers in Genetics</i> , 2021, 12, 642981.	1.1	7
514	Heterogeneous Response to Immunotherapy in a Patient with Tonsillar Squamous Cell Carcinoma Assessed by 18F-FDG PET/CT. <i>Diagnostics</i> , 2021, 11, 348.	1.3	4
515	Future role of [18F]-FDG PET/CT in patients with bladder cancer in the new era of neoadjuvant immunotherapy? • <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 139-141.	0.8	0
516	Early Gastrointestinal Progression to Immunotherapy in Lung Cancer: A Report of Two Cases. <i>Case Reports in Oncological Medicine</i> , 2021, 2021, 1-5.	0.2	2
517	Immunogenic Cell Death Inducing Fluorinated Mitochondria-Disrupting Helical Polypeptide Synergizes with PD-L1 Immune Checkpoint Blockade. <i>Advanced Science</i> , 2021, 8, 2001308.	5.6	31
518	Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. <i>European Journal of Immunology</i> , 2021, 51, 544-556.	1.6	71

#	ARTICLE	IF	CITATIONS
519	Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. <i>Cancers</i> , 2021, 13, 651.	1.7	7
520	Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 501-509.	1.5	4
521	Apport de la TEP-TDM au 18F-FDG chez des patients avec cancer bronchique non À petites cellules ou mélanome métastatique traités par immunothérapie. <i>Medecine Nucleaire</i> , 2021, 45, 59-69.	0.2	0
522	Baseline Hedgehog Pathway Activation and Increase of Plasma Wnt1 Protein Are Associated with Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 1107.	1.7	16
523	Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2021, 4, e211136.	2.8	43
524	Paradigms on Immunotherapy Combinations with Chemotherapy. <i>Cancer Discovery</i> , 2021, 11, 1353-1367.	7.7	197
525	Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer. <i>Scientific Reports</i> , 2021, 11, 6956.	1.6	3
526	Predictive resistance factors in lung cancer patients treated with Nivolumab. Retrospective study. <i>Bulletin Du Cancer</i> , 2021, 108, 250-265.	0.6	3
527	Hyperprogressive disease after radiotherapy combined with anti-PD-1 therapy in renal cell carcinoma: a case report and review of the literature. <i>BMC Urology</i> , 2021, 21, 42.	0.6	6
528	Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. , 2021, 9, e001882.		12
529	Safety of current immune checkpoint inhibitors in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 651-667.	1.0	4
530	Hyperprogression in Patients With Cancer Receiving Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2021, 4, e211839.	2.8	12
531	Atypical Response Patterns in Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors—Navigating the Radiologic Potpourri. <i>Cancers</i> , 2021, 13, 1689.	1.7	7
532	Vaincre les résistances aux antagonistes de checkpoint en augmentant l'immunogénicité de la tumeur. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2021, 205, 340-349.	0.0	0
533	Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics. <i>Indian Journal of Radiology and Imaging</i> , 2021, 31, 345-349.	0.3	2
534	Hyperprogressive Disease: Main Features and Key Controversies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3736.	1.8	18
535	Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs). <i>Clinical and Translational Oncology</i> , 2021, 23, 1782-1793.	1.2	9
536	Depleting Tumor Cells Expressing Immune Checkpoint Ligands—A New Approach to Combat Cancer. <i>Cells</i> , 2021, 10, 872.	1.8	2

#	ARTICLE	IF	CITATIONS
537	Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas. <i>Blood Reviews</i> , 2021, 50, 100832.	2.8	5
538	Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy. <i>Nature Communications</i> , 2021, 12, 2425.	5.8	75
539	Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets. <i>Frontiers in Pharmacology</i> , 2021, 12, 650388.	1.6	13
540	Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1634-1647.	3.0	28
541	PET Molecular Imaging: A Holistic Review of Current Practice and Emerging Perspectives for Diagnosis, Therapeutic Evaluation and Prognosis in Clinical Oncology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4159.	1.8	41
542	The Future of Clinical Trial Design in Oncology. <i>Cancer Discovery</i> , 2021, 11, 822-837.	7.7	32
543	Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature. <i>Frontiers in Immunology</i> , 2021, 12, 608292.	2.2	10
544	Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy. <i>Gut</i> , 2022, 71, 734-745.	6.1	177
545	Kinetics of the neutrophil-lymphocyte ratio during PD-1 inhibition as a prognostic factor in advanced hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 2189-2199.	1.9	26
546	A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. , 2021, 9, e002032.		6
548	The genomic characteristics of different progression patterns in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2021, 9, 779-779.	0.7	4
549	Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy. <i>Medicine (United States)</i> , 2021, 100, e25773.	0.4	7
550	Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. , 2021, 9, e002350.		11
551	The role of positron emission tomography in different types of malignant lymphomas: the results of 2020. <i>Journal of Modern Oncology</i> , 2021, 23, 192-200.	0.1	0
552	Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma. <i>BMC Pulmonary Medicine</i> , 2021, 21, 148.	0.8	20
553	M5C regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 2172-2192.	1.3	15
554	Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab048.	1.4	23
555	Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features. <i>Cancers</i> , 2021, 13, 2935.	1.7	13

#	ARTICLE	IF	CITATIONS
556	Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy. <i>Nature Immunology</i> , 2021, 22, 1052-1063.	7.0	61
557	The dark side of immunotherapy. <i>Annals of Translational Medicine</i> , 2021, 9, 1041-1041.	0.7	12
558	Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer. <i>Cancer Medicine</i> , 2021, 10, 5375-5391.	1.3	6
559	Immune Aging and Immunotherapy in Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7016.	1.8	30
560	The Clinical and Biological Effects of PD-1 Expression on Tumor Cells in Diffuse Large B-Cell Lymphoma. <i>Hemato</i> , 2021, 2, 368-381.	0.2	1
561	Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer. <i>Chinese Medical Journal</i> , 2021, 134, 1780-1788.	0.9	7
562	Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 + Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. <i>Cancers</i> , 2021, 13, 3186.	1.7	11
563	Advancing to the era of cancer immunotherapy. <i>Cancer Communications</i> , 2021, 41, 803-829.	3.7	90
564	Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1159-1169.	1.2	13
565	TGF- β 2 inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model. <i>PLoS ONE</i> , 2021, 16, e0252620.	1.1	16
566	Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer. <i>Disease Markers</i> , 2021, 2021, 1-10.	0.6	13
567	Cytoreductive Nephrectomy Promoted Abscopal Effect of Camrelizumab Combined With Radiotherapy for Metastatic Renal Cell Carcinoma: A Case Report and Review of the Literature. <i>Frontiers in Immunology</i> , 2021, 12, 646085.	2.2	4
568	Immune checkpoint inhibitors: current status. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2021-002954.	0.8	1
569	Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3014-3028.	1.3	9
570	Inmunoterapia en oncologÃa de las vÃas aerodigestivas superiores. <i>EMC - OtorrinolaringologÃa</i> , 2021, 50, 1-20.	0.0	0
571	Cancer Immunotherapies: From Efficacy to Resistance Mechanisms â€œ Not Only Checkpoint Matters. <i>Frontiers in Immunology</i> , 2021, 12, 690112.	2.2	42
572	Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report. <i>Anticancer Research</i> , 2021, 41, 3699-3706.	0.5	5
573	Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. <i>Hepatology Research</i> , 2021, 51, 979-989.	1.8	20

#	ARTICLE	IF	CITATIONS
574	Updated Trends in Imaging Practices for Pancreatic Neuroendocrine Tumors (PNETs): A Systematic Review and Meta-Analysis to Pave the Way for Standardization in the New Era of Big Data and Artificial Intelligence. <i>Frontiers in Oncology</i> , 2021, 11, 628408.	1.3	4
575	Hyperprogression under immunotherapy: a new form of immunotherapy response? a narrative literature review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3276-3291.	1.3	15
576	Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Pharmacology</i> , 2021, 12, 678409.	1.6	15
577	Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough. <i>Cancers</i> , 2021, 13, 3492.	1.7	3
578	Current Imaging Evaluation of Tumor Response to Advanced Medical Treatment in Metastatic Renal-Cell Carcinoma: Clinical Implications. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 6930.	1.3	4
579	Non-neoplastic inflammatory pseudotumor of the lung after immunotherapy for melanoma: A diagnostic pitfall on fine needle aspiration biopsy of lung. <i>Diagnostic Cytopathology</i> , 2021, 49, 1150-1154.	0.5	1
580	Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 579-588.	2.0	27
581	Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08). <i>Gastric Cancer</i> , 2022, 25, 235-244.	2.7	17
582	Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 883-887.	2.3	5
583	Toward prediction of abscopal effect in radioimmunotherapy: Pre-clinical investigation. <i>PLoS ONE</i> , 2021, 16, e0255923.	1.1	7
584	Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies. <i>ELife</i> , 2021, 10, .	2.8	33
585	Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2069-2077.	1.2	13
586	Hyperprogression After Immunotherapy for Primary Small Cell Neuroendocrine Carcinoma of the Ureter: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 696422.	1.3	4
587	PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort. <i>Clinical Lung Cancer</i> , 2022, 23, 43-51.	1.1	11
588	Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2022, 9, HEP41.	4.2	2
589	Immune PET Imaging. <i>Radiologic Clinics of North America</i> , 2021, 59, 875-886.	0.9	2
590	NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images. <i>Cancers</i> , 2021, 13, 4543.	1.7	14
591	Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1. <i>Clinical Lung Cancer</i> , 2021, 22, 381-389.	1.1	4

#	ARTICLE	IF	CITATIONS
592	Case Report: Immune and Genomic Characteristics Associated With Hyperprogression in a Patient With Metastatic Deficient Mismatch Repair Gastrointestinal Cancer Treated With Anti-PD-1 Antibody. <i>Frontiers in Immunology</i> , 2021, 12, 749204.	2.2	5
593	Effector T ^H cell responses unleashed by regulatory T ^H cell ablation exacerbate oral squamous cell carcinoma. <i>Cell Reports Medicine</i> , 2021, 2, 100399.	3.3	11
594	Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target. <i>Journal of Hematology and Oncology</i> , 2021, 14, 147.	6.9	52
595	Hyperprogression: A Unique Phenomenon of Progression of Existing Tumor Secondary to Immunotherapy. <i>Cureus</i> , 2021, 13, e17992.	0.2	1
596	Recombinant cancer nanovaccine for targeting tumor-associated macrophage and remodeling tumor microenvironment. <i>Nano Today</i> , 2021, 40, 101244.	6.2	16
597	Immunotherapy for Head and Neck Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1021-1037.	0.9	8
598	PI3K γ inhibitor plus radiation enhances the antitumor immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model. <i>European Journal of Cancer</i> , 2021, 157, 450-463.	1.3	13
599	Image-guided cancer immunotherapy. , 2022, , 427-467.		0
600	Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy. <i>Korean Journal of Radiology</i> , 2021, 22, 366.	1.5	9
601	Tumors: <i>Oto-Rhino-Laryngology</i> . , 2021, , 1-12.		0
602	Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100115.	0.6	3
603	Immune-Checkpoint Inhibitors in B-Cell Lymphoma. <i>Cancers</i> , 2021, 13, 214.	1.7	29
604	Hyperprogression: A novel response pattern under immunotherapy. <i>Clinical and Translational Medicine</i> , 2020, 10, e167.	1.7	22
605	Molecular and Functional Imaging in Oncology Therapy Response. <i>Medical Radiology</i> , 2020, , 255-272.	0.0	2
606	Janus or Hydra: The Many Faces of T Helper Cells in the Human Tumour Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1224, 35-51.	0.8	10
607	Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 143-166.	0.8	3
608	Importancia de la imagen en la valoración de la respuesta al tratamiento con inmunoterapia del cáncer de pulmón. <i>Archivos De Bronconeumología</i> , 2020, 56, 380-389.	0.4	4
609	Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102965.	2.0	17

#	ARTICLE	IF	CITATIONS
610	Double immune checkpoint blockade in advanced NSCLC. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102980.	2.0	12
611	Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 341-355.	12.5	347
612	Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. <i>Oncolimmunology</i> , 2020, 9, 1710052.	2.1	17
613	Immune checkpoint inhibitor-associated hypercalcaemia. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1598-1608.	0.4	12
614	Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report. <i>Anti-Cancer Drugs</i> , 2021, 32, 222-225.	0.7	3
618	Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2020, 111, 1969-1978.	1.7	13
619	A combination of intra- and peritumoral features on baseline CT scans is associated with overall survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a multi-agent multi-site study. , 2019, , .		4
620	Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. <i>JCI Insight</i> , 2018, 3, .	2.3	156
621	PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. <i>European Radiology Experimental</i> , 2020, 4, 63.	1.7	38
622	Use of Radiomics to Predict Response to Immunotherapy of Malignant Tumors of the Digestive System. <i>Medical Science Monitor</i> , 2020, 26, e924671.	0.5	10
623	Acute myelomonocytic leukemia during pembrolizumab treatment for non-small cell lung cancer: A case report. <i>World Journal of Clinical Cases</i> , 2020, 8, 2833-2840.	0.3	3
624	Hyperprogression after immunotherapy in HNC: literature review and our experience. <i>International Journal of Radiology and Radiation Oncology</i> , 0, , 001-002.	0.1	3
625	Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review. <i>Oncotarget</i> , 2017, 8, 57889-57897.	0.8	26
626	Overexpression of RAD51B predicts a preferable prognosis for non-small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 91471-91480.	0.8	8
627	Therapeutic induction of high endothelial venules (HEVs) to enhance T-cell infiltration in tumors. <i>Oncotarget</i> , 2017, 8, 99207-99208.	0.8	9
628	Surrogate study endpoints in the era of cancer immunotherapy. <i>Annals of Translational Medicine</i> , 2018, 6, S27-S27.	0.7	18
629	The role of endobronchial ultrasound transbronchial needle aspiration for programmed death ligand 1 testing and next generation sequencing in advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2019, 7, 351-351.	0.7	14
630	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018, 7, 428-436.	1.3	7

#	ARTICLE	IF	CITATIONS
631	Challenges of evaluating immunotherapy efficacy in solid tumors. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 853-861.	0.7	8
632	T _{FR} Cells Inhibit Anti-Tumor Immunity and are Responsive to Immune Checkpoint Blockade. SSRN Electronic Journal, 0, , .	0.4	1
633	Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma. ClinicoEconomics and Outcomes Research, 2020, Volume 12, 241-252.	0.7	4
634	Rapid Progressive Disease After Nivolumab Therapy in Three Patients with Metastatic Renal Cell Carcinoma. In Vivo, 2017, 31, 769-771.	0.6	17
635	The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 162-174.	0.4	38
636	Update on tumor metabolism and patterns of response to immunotherapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 175-185.	0.4	8
637	Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy. Cancers, 2021, 13, 48.	1.7	20
639	Biomarkers of immunotherapy in non-small cell lung cancer (Review). Oncology Letters, 2020, 20, 1-1.	0.8	8
640	Tumour Regression via Integrative Regulation of Neurological, Inflammatory, and Hypoxic Tumour Microenvironment. Biomolecules and Therapeutics, 2020, 28, 119-130.	1.1	13
641	Gastric perforation due to nivolumab related tumor flare. Indian Journal of Cancer, 2019, 56, 374.	0.2	3
642	Hyperprogressive disease after nivolumab in a patient with microsatellite instability-high ampullary cancer. Journal of Cancer Research and Practice, 2019, 6, 50.	0.2	2
643	Coalition Forces of Immunologists and Oncologists for Defeating Cancer. Immune Network, 2020, 20, e1.	1.6	4
644	Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy. Immune Network, 2020, 20, e8.	1.6	19
645	Precision Medicine in Oncology: Glossary of Relevant Scientific Terms. UNIPA Springer Series, 2021, , 411-416.	0.1	0
646	Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench. Oncotarget, 2021, 13, 13-15.	0.8	0
647	Tumor Growth Rate After Nadir Is Associated With Survival in Patients With EGFR-Mutant Non-Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. JCO Precision Oncology, 2021, 5, 1603-1610.	1.5	4
648	Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy. Expert Review of Anticancer Therapy, 2021, 21, 1355-1370.	1.1	6
649	Toripalimab in an advanced non-small cell lung cancer patient with poor general condition after multiline treatment: a case report. Journal of International Medical Research, 2021, 49, 030006052110429.	0.4	3

#	ARTICLE	IF	CITATIONS
650	Docetaxel increases the risk of severe infections in the treatment of non-small cell lung cancer: a meta-analysis. <i>Oncoscience</i> , 2018, 5, 220-238.	0.9	6
651	Response to salvage chemotherapy after progression on nivolumab in patients with recurrent/metastatic head and neck squamous cell carcinoma. <i>Japanese Journal of Head and Neck Cancer</i> , 2019, 45, 41-45.	0.0	1
652	Head and Neck Tumors in Older Adults: Systemic Treatments and Combination with Local Strategies. , 2019, , 1-13.		0
653	Les avancÃ©es dans la prise en charge des cancers bronchopulmonaires : ce qui change pour le rÃ©animateur. <i>Medecine Intensive Reanimation</i> , 2019, 28, 290-299.	0.1	0
654	2. Cancer Immunotherapy: A Novel Approach to Cancer Treatment. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2019, 50, 107-111.	0.1	0
655	Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab. <i>Cureus</i> , 2019, 11, e4862.	0.2	3
656	CritÃ©res d'Ã©valuation radiologique des patients sous immunothÃ©rapie. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, S457-S467.	0.0	0
659	Gastrointestinal Toxicities of Immunotherapy. , 2020, , 201-222.		0
661	Hyperprogressive Disease in an Advanced Stage Colon Cancer Patient on Pembrolizumab: A Case Report. <i>Cureus</i> , 2020, 12, e7764.	0.2	4
662	Hyperprogression of Liver Metastasis With Neoadjuvant Immunotherapy for Soft Tissue Sarcoma. <i>Cureus</i> , 2020, 12, e8575.	0.2	4
663	Radio-Immunotherapy: A Case Report of "Abscopal Hyper-Progression"? <i>Cureus</i> , 2020, 12, e10117.	0.2	2
664	Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11726.	1.8	3
665	TCF-1+ PD-1+ CD8+T cells are associated with the response to PD-1 blockade in non-small cell lung cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2653-2660.	1.2	4
667	Therapy Response Imaging in Genitourinary Malignancies. <i>Medical Radiology</i> , 2020, , 139-157.	0.0	0
668	Is hyperprogressive disease a specific phenomenon of immunotherapy?. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, .	0.5	1
669	Response evaluation after immunotherapy in NSCLC. <i>Medicine (United States)</i> , 2020, 99, e23815.	0.4	8
670	Important Points to Consider When Evaluating the Response to Drug Therapy for Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2020, 60, 942-950.	0.0	0
671	Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score. <i>Translational Oncology</i> , 2022, 15, 101254.	1.7	4

#	ARTICLE	IF	CITATIONS
672	Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs. <i>Immune Network</i> , 2020, 20, e48.	1.6	10
673	Response Evaluations for Precision Cancer Therapy and Immunotherapy. <i>Medical Radiology</i> , 2020, , 15-27.	0.0	0
674	Therapy Response Imaging in Thoracic Malignancy. <i>Medical Radiology</i> , 2020, , 79-97.	0.0	0
675	Efficacy Considerations in Phase I Trials. , 2020, , 159-183.		0
676	Head and Neck Tumors in Older Adults: Systemic Treatments and Combination with Local Strategies. , 2020, , 759-771.		0
677	Radiosensitizers in the Era of Immuno-Oncology. <i>Cancer Drug Discovery and Development</i> , 2020, , 339-360.	0.2	0
679	EVALUATION OF THE EFFECTIVENESS OF MODERN IMMUNOTHERAPY. <i>Voprosy Onkologii</i> , 2020, 66, 211-217.	0.1	0
680	Biomarkers for pediatric cancer detection: latest advances and future perspectives. <i>Biomarkers in Medicine</i> , 2020, 14, 391-400.	0.6	3
681	Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma. <i>Anticancer Research</i> , 2021, 41, 5767-5773.	0.5	7
682	Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 761110.	1.3	5
683	Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. <i>Journal of Histochemistry and Cytochemistry</i> , 2022, 70, 53-81.	1.3	6
684	Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 5160.	1.0	20
685	Approaches to metastatic skin melanoma therapy in 2020: a dynamic way forward. <i>Meditinskiy Sovet</i> , 2020, , 80-93.	0.1	0
686	The lymphocyte-to-monocyte ratio could predict the efficacy of PD-1 inhibitors in patients with advanced cancer. <i>Translational Cancer Research</i> , 2020, 9, 4111-4120.	0.4	5
687	Immunotherapy for regional, recurrent and metastatic head and neck cancer: recent advances and future directions. <i>Medical Alphabet</i> , 2020, , 60-69.	0.0	0
688	Imaging and Radiomics of Immuno-oncology of Primary and Secondary Gastrointestinal Malignancies. <i>Digestive Disease Interventions</i> , 2020, 04, 373-381.	0.3	0
689	How I Treat Nonâ€“Small Cell Lung Cancer Refractory to Immunotherapy. <i>Cancer Journal (Sudbury, Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	1.0	1
692	How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. <i>American Journal of Cancer Research</i> , 2019, 9, 1546-1553.	1.4	37

#	ARTICLE	IF	CITATIONS
715	A case of recurrent metastatic tongue cancer with complete response and drug therapy discontinuation after 2 years of nivolumab administration. <i>Journal of Japanese Society of Oral Oncology</i> , 2021, 33, 195-202.	0.0	0
716	Electrolyte and Acid-Base Disorders Associated with Cancer Immunotherapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 922-933.	2.2	15
717	Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma. <i>Bioscience Reports</i> , 2022, 42, .	1.1	13
718	The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems. <i>Frontiers in Oncology</i> , 2021, 11, 704999.	1.3	8
719	Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma. <i>HemaSphere</i> , 2022, 6, e672.	1.2	5
720	Programmed death ligand 1 signals in cancer cells. <i>Nature Reviews Cancer</i> , 2022, 22, 174-189.	12.8	133
721	Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 147-164.	0.9	5
722	Monitoring tumor growth rate to predict immune checkpoint inhibitorsâ€™™ treatment outcome in advanced NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110583.	1.4	2
724	Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab. <i>Acta Medica Okayama</i> , 2020, 74, 423-425.	0.1	2
725	Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer. <i>Expert Reviews in Molecular Medicine</i> , 2022, 24, e16.	1.6	1
726	Role of Primary Care in Detection of Subsequent Primary Cancers. <i>Journal for Nurse Practitioners</i> , 2022, , .	0.4	1
727	Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1645-1649.	0.5	2
728	The Landscape of Nanovectors for Modulation in Cancer Immunotherapy. <i>Pharmaceutics</i> , 2022, 14, 397.	2.0	4
729	Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center. <i>Cancers</i> , 2022, 14, 1330.	1.7	0
730	Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2847.	1.8	19
731	Pretreatment Positron Emission Tomography with ¹⁸ F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma. <i>Oncology</i> , 2022, 100, 320-330.	0.9	5
732	A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy. <i>Npj Precision Oncology</i> , 2022, 6, 19.	2.3	20
733	Artificial Intelligence-based Radiomics in the Era of Immuno-oncology. <i>Oncologist</i> , 2022, 27, e471-e483.	1.9	15

#	ARTICLE	IF	CITATIONS
734	Current Understanding and Future Perspectives on Hyperprogressive Disease Highlight the Tumor Microenvironment. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 1059-1078.	1.0	0
735	Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review. <i>Frontiers in Nutrition</i> , 2022, 9, 810472.	1.6	5
736	Multiple eruptive squamoproliferative lesions during anti-PD1 immunotherapy for metastatic melanoma: Pathogenesis, immunohistochemical analysis and treatment. <i>Dermatologic Therapy</i> , 2022, , e15472.	0.8	1
737	Recurrent cervical cancer with PD-L1 amplification treated with nivolumab: A case enrolled in the BELIEVE trial. <i>Journal of Obstetrics and Gynaecology Research</i> , 2022, , .	0.6	1
738	Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2323-2341.	3.3	48
739	Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials. , 2022, 10, e004273.		10
740	Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs. <i>European Journal of Cancer</i> , 2022, 167, 42-53.	1.3	2
741	Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy. <i>Hepatology Research</i> , 2022, 52, 298-307.	1.8	31
742	Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment. <i>Cancers</i> , 2021, 13, 6231.	1.7	13
743	A Case of Recurrence of HER2-Positive Esophagogastric Junction Cancer in Which Fourth-Line Treatment with Nivolumab Was Effective after Pseudo Progression-Like Growth. <i>Japanese Journal of Gastroenterological Surgery</i> , 2021, 54, 853-860.	0.0	0
744	Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 939-947.	3.2	10
745	Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives. <i>Precision Clinical Medicine</i> , 2021, 4, 258-270.	1.3	18
746	Different subpopulations of regulatory T cells in human autoimmune disease, transplantation, and tumor immunity. <i>MedComm</i> , 2022, 3, e137.	3.1	11
747	Hyper-Progressive Disease (HPD) during Immune Checkpoint Inhibitor (ICI) Therapy. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, 43, .	0.1	0
748	CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab. <i>BMC Cancer</i> , 2022, 22, 418.	1.1	3
749	Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2791-2799.	2.0	3
750	Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	1
751	Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy. <i>EBioMedicine</i> , 2022, 79, 103987.	2.7	9

#	ARTICLE	IF	CITATIONS
752	Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112949.	2.5	6
758	Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma.. <i>EXCLI Journal</i> , 2022, 21, 250-268.	0.5	10
759	Rapid subcutaneous progression after immunotherapy in pretreated patients with metastatic carcinoma: two case reports. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210942.	0.4	1
761	Effect of Particle Carriers for Intraperitoneal Drug Delivery on the Course of Ovarian Cancer and Its Immune Microenvironment in a Mouse Model. <i>Pharmaceutics</i> , 2022, 14, 687.	2.0	4
766	Advanced Immune Cell Profiling by Multiparameter Flow Cytometry in Humanized Patient-Derived Tumor Mice. <i>Cancers</i> , 2022, 14, 2214.	1.7	5
767	A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 607-616.	1.3	5
768	T Lymphocyte Exhaustion During Human and Experimental Visceral Leishmaniasis. <i>Frontiers in Immunology</i> , 2022, 13, 835711.	2.2	14
769	Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer. <i>International Immunopharmacology</i> , 2022, 108, 108803.	1.7	5
770	Red Blood Cells-Based Vaccines for Ameliorating Cancer Chemoimmunotherapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
771	Lung Inflammation Predictors in Combined Immune Checkpoint-Inhibitor and Radiation Therapy—Proof-of-Concept Animal Study. <i>Biomedicines</i> , 2022, 10, 1173.	1.4	3
772	Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy. <i>Cells</i> , 2022, 11, 1758.	1.8	3
773	FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 707-719.	2.5	10
774	New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Vaccines</i> , 2022, 10, 885.	2.1	2
775	Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer. <i>PLoS ONE</i> , 2022, 17, e0269115.	1.1	2
776	MSI colorectal cancer, all you need to know. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101983.	0.7	8
777	PET-CT in Clinical Adult Oncology—VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors. <i>Cancers</i> , 2022, 14, 2835.	1.7	4
778	A Decade of Success in Melanoma Immunotherapy and Targeted Therapy: What Every Radiologist Should Know. <i>Journal of Computer Assisted Tomography</i> , 2022, 46, 621-632.	0.5	2
779	Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. , 2022, 10, e004984.		28

#	ARTICLE	IF	CITATIONS
780	Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
781	iRECIST and atypical patterns of response to immuno-oncology drugs. , 2022, 10, e004849.		12
782	¹⁸ F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer. <i>Radiology</i> , 2022, 304, 246-264.	3.6	14
783	Bv8 Blockade Sensitizes Anti-PD1 Therapy Resistant Tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
784	Combination therapy regimens in the treatment of metastatic renal cell carcinoma: A review. <i>Journal of Modern Oncology</i> , 2022, 24, 191-198.	0.1	0
785	The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7839.	1.8	13
786	Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
787	Clinical outcomes of hyperprogression based on volumetry in non-small cell lung cancer after immune checkpoint inhibitor treatment. <i>Thoracic Cancer</i> , 2022, 13, 2170-2179.	0.8	4
788	Immunotherapies and renal injury. <i>Current Opinion in Toxicology</i> , 2022, 31, 100362.	2.6	0
789	Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. <i>European Journal of Cancer</i> , 2022, 172, 387-399.	1.3	4
790	Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, .	0.4	4
791	Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3139-3147.	1.2	7
792	Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy?. , 2022, 10, e004848.		14
793	Antitumor efficacy of ⁹⁰ Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors. , 2022, 10, e005060.		7
794	Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
795	Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
796	Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy. <i>Lung Cancer</i> , 2022, 173, 28-34.	0.9	3
797	Radiation Therapy for Metastatic Lung Cancer: Liver Metastasis. <i>Medical Radiology</i> , 2022, , .	0.0	0

#	ARTICLE	IF	CITATIONS
798	Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report. <i>Current Oncology</i> , 2022, 29, 6203-6210.	0.9	1
799	What does radiomics do in <sc>PD-1</sc> blockade therapy of <sc>NSCLC</sc> patients?. <i>Thoracic Cancer</i> , 2022, 13, 2669-2680.	0.8	2
800	Prognostic role of indoleamine 2,3-dioxygenase 1 expression in solid tumors: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
801	<sc>PD-1</sc>/<sc>PD-1</sc> signalling promotes colorectal cancer cell migration ability through <sc>RAS</sc>/<sc>MEK</sc>/<sc>ERK</sc>. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2022, 49, 1281-1293.	0.9	7
802	Echocardiography-Assessed Changes of Left and Right Ventricular Cardiac Function May Correlate with Progression of Advanced Lung Cancer—A Generating Hypothesis Study. <i>Cancers</i> , 2022, 14, 4770.	1.7	4
803	Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 5171.	1.0	2
804	Th17, Th22, and Myeloid-Derived Suppressor Cell Population Dynamics and Response to IL-6 in 4T1 Mammary Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10299.	1.8	2
805	Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>British Journal of Cancer</i> , 2022, 127, 2034-2042.	2.9	8
806	A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 827-840.	2.0	3
807	Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression?. <i>World Journal of Clinical Oncology</i> , 2022, 13, 729-737.	0.9	0
808	Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 5136-5148.	3.2	8
809	Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy. , 2022, 10, e005292.		22
810	Fibrinogen like protein-1 knockdown suppresses the proliferation and metastasis of TU-686 cells and sensitizes laryngeal cancer to LAG-3 blockade. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211268.	0.4	2
811	Treg-Dominant Tumor Microenvironment Is Responsible for Hyperprogressive Disease after PD-1 Blockade Therapy. <i>Cancer Immunology Research</i> , 2022, 10, 1386-1397.	1.6	18
812	High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy. <i>European Journal of Cancer</i> , 2022, 177, 80-93.	1.3	12
813	Advances and challenges of immunocheckpoint inhibitors in the treatment of primary liver cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
814	Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
815	Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis. <i>Journal of Immunotherapy</i> , 2023, 46, 43-55.	1.2	4

#	ARTICLE	IF	CITATIONS
816	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
817	Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score. <i>Cancers</i> , 2022, 14, 5078.	1.7	9
819	Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13241.	1.8	9
820	Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy. <i>Acta Biomaterialia</i> , 2022, 154, 401-411.	4.1	3
821	F-18 Fluciclovine PET-CT Findings and Pseudoprogession on Immunotherapy. <i>Cureus</i> , 2022, , .	0.2	0
822	Immune checkpoint inhibitors combined with tyrosine kinase inhibitors is the treatment option of previously treated advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration. <i>Translational Lung Cancer Research</i> , 2022, 11, 2164-2166.	1.3	1
823	Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan. <i>Gastric Cancer</i> , 2023, 26, 132-144.	2.7	2
824	Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non-“Small Cell Lung Cancer. <i>Radiographics</i> , 2022, 42, 1956-1974.	1.4	4
825	Invited Commentary: Pearls and Pitfalls in Imaging Evaluation of Lung Cancer Immunotherapy. <i>Radiographics</i> , 2022, 42, E205-E207.	1.4	0
826	Unlocking the Potential of Immuno-Oncology in Advanced Cutaneous Squamous Cell Carcinoma: Role of Checkpoint Blockade. <i>EMJ Dermatology</i> , 0, , 2-10.	0.0	0
827	Unlocking the Potential of Immuno-Oncology in Advanced Cutaneous Squamous Cell Carcinoma: Role of Checkpoint Blockade. <i>EMJ Dermatology</i> , 0, , 2-10.	0.0	0
828	Development of models for predicting the objective response of immune checkpoint inhibitor therapy in patients with nonsmall-cell lung cancer. <i>Digital Medicine</i> , 2022, 8, 27.	0.1	0
829	The radiological appearances of lung cancer treated with immunotherapy. <i>British Journal of Radiology</i> , 2023, 96, .	1.0	1
830	Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review. , 2022, 1, 225-234.		3
831	Combination of photosensitizer and immune checkpoint inhibitors for improving the efficacy of tumor immunotherapy. <i>International Journal of Pharmaceutics</i> , 2022, 629, 122384.	2.6	0
832	Emerging and Evolving Concepts in Cancer Immunotherapy Imaging. <i>Radiology</i> , 2023, 306, 32-46.	3.6	10
834	Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy. <i>Seminars in Immunopathology</i> , 0, , .	2.8	2
835	Development of Radiomic-Based Model to Predict Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. <i>Cancers</i> , 2022, 14, 5931.	1.7	6

#	ARTICLE	IF	CITATIONS
836	Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti-PD-1 immunotherapy. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	14
837	Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. <i>Nature Reviews Urology</i> , 2023, 20, 133-157.	1.9	46
838	Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
839	PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
840	Extremely high infiltration of CD8+PD-L1+ cells detected in a stage III non-small cell lung cancer patient exhibiting hyperprogression during anti-PD-L1 immunotherapy after chemoradiation: A case report. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
841	Considerations for Imaging of Malignant Pleural Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group. <i>Journal of Thoracic Oncology</i> , 2023, 18, 278-298.	0.5	6
842	Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution. <i>Genome Medicine</i> , 2022, 14, .	3.6	15
843	Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 6089.	1.7	6
844	Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis inhibitor. <i>ESMO Open</i> , 2022, 7, 100630.	2.0	1
845	PET/CT in Non-Hodgkin Lymphoma: An Update. <i>Seminars in Nuclear Medicine</i> , 2023, 53, 320-351.	2.5	13
846	PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	36
847	Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma. <i>ESMO Open</i> , 2022, 7, 100644.	2.0	1
849	The Educational Program of Macrophages toward a Hyperprogressive Disease-Related Phenotype Is Orchestrated by Tumor-Derived Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15802.	1.8	0
850	Safety Profiling of Tumor-targeted T Cell-Bispecific Antibodies with Alveolus Lung- and Colon-on-Chip. <i>Bio-protocol</i> , 2023, 13, .	0.2	1
851	Synergistic effect of glutathione and IgG4 in immune evasion and the implication for cancer immunotherapy. <i>Redox Biology</i> , 2023, 60, 102608.	3.9	2
852	Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome. <i>Cancers</i> , 2023, 15, 321.	1.7	21
853	Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer. <i>ImmunoTargets and Therapy</i> , 0, Volume 12, 1-16.	2.7	1
854	Tumor Hyperprogression and Pseudoprogression After Immunotherapy. , 2023, , 1-24.		0

#	ARTICLE	IF	CITATIONS
855	Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. <i>Cancer Cell</i> , 2023, 41, 304-322.e7.	7.7	34
856	Advanced T and Natural Killer Cell Therapy for Glioblastoma. <i>Journal of Korean Neurosurgical Society</i> , 2023, 66, 356-381.	0.5	0
857	Phytochemical Constituents and Derivatives of <i>Cannabis sativa</i> ; Bridging the Gap in Melanoma Treatment. <i>International Journal of Molecular Sciences</i> , 2023, 24, 859.	1.8	8
858	Targeting regulatory T cells in gastric cancer: Pathogenesis, immunotherapy, and prognosis. <i>Biomedicine and Pharmacotherapy</i> , 2023, 158, 114180.	2.5	5
859	FDG-PET findings associated with various medical procedures and treatments. <i>Japanese Journal of Radiology</i> , 0, , .	1.0	1
860	[18F]FDG PET/CT Imaging in Cancer Treatment with Checkpoint Inhibitors. , 2023, , 1-40.		0
861	Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review. <i>Seminars in Oncology</i> , 2022, 49, 439-455.	0.8	3
862	Paradoxical cancer cell stimulation by IFN γ drives tumor hyperprogression upon checkpoint blockade immunotherapy. <i>Cancer Cell</i> , 2023, 41, 229-231.	7.7	4
863	Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer. <i>Korean Journal of Internal Medicine</i> , 2023, 38, 218-225.	0.7	5
864	Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials. <i>Oncologist</i> , 2023, 28, e205-e211.	1.9	4
865	Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy. <i>British Journal of Dermatology</i> , 2023, 188, 112-121.	1.4	2
866	MUC1 promotes lung metastases of liver cancer by impairing anti-tumor immunity. <i>Discover Oncology</i> , 2023, 14, .	0.8	2
867	Image-based response assessment during immunotherapy in skin cancer. <i>JDDG - Journal of the German Society of Dermatology</i> , 2023, 21, 107-114.	0.4	0
868	FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects. <i>Cancers</i> , 2023, 15, 1063.	1.7	4
869	Life-threatening hyper-progression on immunotherapy revealed as pseudo-progression in DNA mismatch repair deficiency: a case report. <i>Journal of Gastrointestinal Oncology</i> , 2023, 14, 435-441.	0.6	0
870	Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence. <i>Cancers</i> , 2023, 15, 1314.	1.7	2
871	Bildgestützte Beurteilung des Ansprechens auf Immuntherapien bei Hauttumoren. <i>JDDG - Journal of the German Society of Dermatology</i> , 2023, 21, 107-115.	0.4	0
872	The hypotheses of the immune system's role in carcinogenesis. <i>Genes and Cells</i> , 2021, 16, 82-91.	0.2	2

#	ARTICLE	IF	CITATIONS
874	[18F]FDG PET/CT in the Evaluation of Melanoma Patients Treated with Immunotherapy. <i>Diagnostics</i> , 2023, 13, 978.	1.3	4
876	Advanced CT Imaging, Radiomics, and Artificial Intelligence to Evaluate Immune Checkpoint Inhibitorsâ€™ Effects on Metastatic Renal Cell Carcinoma. <i>Applied Sciences (Switzerland)</i> , 2023, 13, 3779.	1.3	1
877	Immune Checkpoint Blockade Response Biomarkers. , 2023, , 1-34.		0
878	Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment. <i>Molecular Cancer</i> , 2023, 22, .	7.9	18
879	Patterns of Response to Immune Oncology Drugs: How Relevant Are They in SCCHN?. , 2023, , 217-228.		0
880	Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
881	Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	0
882	Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report. <i>Immunotherapy</i> , 2023, 15, 631-639.	1.0	2
883	The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer. <i>Journal of Cancer</i> , 2023, 14, 952-965.	1.2	1
884	Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients. <i>IScience</i> , 2023, 26, 106720.	1.9	1
887	Case report: A combined immunotherapy strategy as a promising therapy for MSI-H colorectal carcinomas with multiple HPD risk factors. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	0
914	Editorial: Optimizing outcomes and addressing adversities of immunotherapy in lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
940	Review of F-18 FDG PET/CT in Evaluating Response to Immunotherapy Treatment. , 2024, , 11-29.		0
946	Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy. <i>Molecular Biology Reports</i> , 2024, 51, .	1.0	1
949	Rapid tumor progression complicated with liver abscess in a patient with gastric cancer receiving nivolumab therapy. <i>International Cancer Conference Journal</i> , 2024, 13, 119-123.	0.2	0
960	Important Biomarkers for Better Evaluation of Checkpoint Inhibitors and Other Immunotherapies in Lung Cancer. , 2024, , 331-351.		0